Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
复制标题
DOI：
10.1056/nejmoa061884
复制
发表时间：
2006-12-14
影响因子：
158.5
通讯作者：
Johnson, David H.
中科院分区：
文献类型：
--
作者：
Sandler, Alan;Gray, Robert;Johnson, David H.
背景：贝伐单抗，一种抗血管内皮生长因子的单克隆抗体，已被证明对多种癌症患者有益。方法：2001年7月至2004年4月，东部肿瘤协作组（ECOG）进行了一项随机研究，其中878例复发或晚期非小细胞肺癌（IIIB或IV期）患者被分配到紫杉醇和卡铂单独化疗（444）或紫杉醇和卡铂加贝伐单抗（434）。化疗每3周给药一次，共6个周期，贝伐珠单抗每3周给药一次，直至疾病进展明显或毒性作用不可耐受。排除患有鳞状细胞肿瘤、脑转移、临床显著咯血或器官功能或体力状态不足（ECOG体力状态>1）的患者。结果：化疗加贝伐单抗组的中位生存期为12.3个月，而单纯化疗组的中位生存期为10.3个月（死亡风险比为0.79; P=0.003）。两组的中位无进展生存期分别为6.2和4.5个月（疾病进展的风险比为0.66; P
BACKGROUND:Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers.METHODS:Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable. Patients with squamous-cell tumors, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded. The primary end point was overall survival.RESULTS:The median survival was 12.3 months in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P=0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P